Factor IX - 2018 Pipeline Insights by Developmental Stage, Product Type, Molecule Type, and Administration Route - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Factor IX -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Factor IX development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Descriptive coverage of pipeline development activities for Factor IX - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Factor IX pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered
1. Report Introduction
2. Factor IX - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Factor IX
4. Comparative Analysis
5. Factor IX Pipeline Products in Clinical Stages
5.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
6. Factor IX Pipeline Products in Non-clinical Stages
6.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities
Other product profiles in the detailed report..
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
8.1 Drug Name : Company NameProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies FeaturedAronora Pfizer Biogen Idec/Swedish Orphan Biovitrum (Sobi) Baxalta Novo Nordisk Emergent Biosolutions CSL Behring ISU ABXIX Grifols
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mpt252/factor_ix_2018?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005444/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/17/2018 09:40 AM/DISC: 12/17/2018 09:41 AM